Provided by Tiger Trade Technology Pte. Ltd.

Evolus Inc.

8.82
+0.04000.46%
Volume:234.57K
Turnover:2.07M
Market Cap:580.84M
PE:-16.75
High:8.98
Open:8.76
Low:8.72
Close:8.78
52wk High:8.98
52wk Low:3.86
Shares:65.85M
Float Shares:51.01M
Volume Ratio:1.42
T/O Rate:0.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5267
EPS(LYR):-0.8010
ROE:-18729.61%
ROA:-5.40%
PB:-18.80
PE(LYR):-11.01

Loading ...

Evolus Price Target Maintained with a $13.00/Share by HC Wainwright & Co.

Dow Jones
·
2 hours ago

August 2026's Leading Growth Companies With Insider Confidence

Simply Wall St.
·
Aug 14

Evolus (EOLS) Stock Jumps On Margin Turn And EBITDA Momentum

Simply Wall St.
·
Aug 07

Apyx Medical Q2 Revenue Beats Estimates on Surgical Aesthetics Growth

Reuters
·
Aug 07

Establishment Labs Q2 Revenue Rises, Beats Estimates

Reuters
·
Aug 06

Mizuho Securities Reaffirms Their Buy Rating on Evolus (EOLS)

TIPRANKS
·
Aug 06

Evolus Inc. Earnings Call Signals Confident Growth

TIPRANKS
·
Aug 06

Evolus Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Evolus Posts Scientific Investor Presentation on Jeuveau, Evolysse HA Fillers, Profhilo Skin-Quality Injectable Portfolio

Reuters
·
Aug 06

Evolus Q2 Revenue Rises 21%, Lifts 2026 Outlook

Reuters
·
Aug 06

Evolus Q2 EPS $(0.12), Sales $84.084M Beat $81.603M Estimate

Benzinga Earnings
·
Aug 06

Evolus Q2 GAAP Operating Loss Narrows to USD 4.5 Million; Revenue Increases 21% to USD 84.1 Million vs Year-Ago Quarter

Reuters
·
Aug 06

Evolus Q2 Product Revenue USD 83.35 Million

Reuters
·
Aug 06

Evolus Outlook FY Sales Growth 11-13%

THOMSON REUTERS
·
Aug 06

Evolus Outlook FY Sales USD 330-337 Million

THOMSON REUTERS
·
Aug 06

Evolus expands strategic partnership with Symatese to commercialize Estyme

TIPRANKS
·
Aug 04

Evolus Expands Symatese Partnership to Commercialize Estyme HA Gels in Canada, Australia, New Zealand

Reuters
·
Aug 04

Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand

THOMSON REUTERS
·
Aug 04

Evolus - Agreement Expected to be Accretive to Evolus International Gross Margins

THOMSON REUTERS
·
Aug 04

Evolus - to Commercialize Estyme in All Markets with Jeuveau and Nuceiva in 2028

THOMSON REUTERS
·
Aug 04